Collaborations at the ASCO Gastrointestinal Cancers Symposium
Melbourne, Australia – 26 January 2024: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), is pleased to announce significant updates and collaborations at the ASCO Gastrointestinal Cancers Symposium held from January 18-20, 2024 at San Francisco, CA. US and international physicians were in attendance.
The OncoSil Medical team met with executives from the Cholangiocarcinoma Foundation to explore possible collaboration in increasing awareness of the OncoSil™ technology. ASCO-GI presented a unique and valuable opportunity for OncoSil Medical to actively engage with a diverse group of international participants, including physicians, Key Opinion Leaders (KOLs), and influential industry leaders. The interactive platform provided a conducive environment for fostering meaningful discussions, sharing insights, and building collaborative relationships. This occasion allowed OncoSil Medical to not only showcase its innovative solutions but also to gain firsthand feedback from esteemed professionals in the field. The exchange of ideas and perspectives during these interactions contributes significantly to the ongoing efforts of OncoSil Medical in staying at the forefront of advancements in cancer treatment.